<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04816240</url>
  </required_header>
  <id_info>
    <org_study_id>ILBS-Cirrhosis-40</org_study_id>
    <nct_id>NCT04816240</nct_id>
  </id_info>
  <brief_title>Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis.</brief_title>
  <official_title>Evaluation of Albumin and Midodrine Versus Albumin Alone in Outcome of Refractory Ascites in Patients With Decompensated Cirrhosis - A Double Blind Randomized Controlled Trial.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Liver and Biliary Sciences, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Liver and Biliary Sciences, India</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The project is about evaluation of albumin and midodrine versus albumin alone in outcome of&#xD;
      refractory ascites in patients with decompensated cirrhosis.&#xD;
&#xD;
      Cirrhosis is a leading cause of disability and mortality worldwide. Cirrhosis occurs in 50%&#xD;
      of patients over 10 years. Decompensated cirrhosis carries a poor prognosis because the&#xD;
      median survival time is about 2 years and it imposes a heavy burden on health care costs&#xD;
      mainly due to the need for repeated hospital admission. The mortality is approximately 40% at&#xD;
      1 year and 50% at 2 years (12.7 per 100,000 population). A lot of times the prognosis is poor&#xD;
      and the main factors leading to it are - AKI/HRS-NAKI, Hyponatremia, Grade of&#xD;
      ascites-Refractory ascites, Sarcopenia, low Mean arterial pressure.&#xD;
&#xD;
      Post review of the literature, it is realized that there are some gap areas -&#xD;
&#xD;
        -  It is unknown whether combination of vasoconstrictor with albumin further decreases the&#xD;
           need for paracentesis in patients of refractory ascites.&#xD;
&#xD;
        -  There are no studies till date on using combination of vasoconstrictor with albumin for&#xD;
           refractory ascites.&#xD;
&#xD;
        -  There are no studies evaluating the prevalence and incidence of HRS-NAKI using the new&#xD;
           definitions in patients with refractory ascites and impact of combining vasoconstrictor&#xD;
           and albumin in improving renal outcomes in these patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population All patients with decompensated cirrhosis with refractory ascites who get&#xD;
      admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who&#xD;
      fulfilthe inclusion criteria, exclusion criteria and provide informed consent&#xD;
&#xD;
        -  Study design Single Centre Placebo Controlled an open level Randomised Controlled Trial&#xD;
&#xD;
        -  Study period 1 year from ethics approval.&#xD;
&#xD;
        -  Sample size Assuming that survival rate with albumin and midodrine is 80%, whereas with&#xD;
           albumin alone is 60% ( ie. 20% absolute difference is observed with alpha of 5% power so&#xD;
           we need to enroll 170 cases allotted in 2 groups further taking 10% as dropout rate. It&#xD;
           was decided to enroll 200 cases allotted in 2 groups randomly by block randomization&#xD;
           method taking block size as 10&#xD;
&#xD;
        -  Intervention Group A will be treated with SMT + Albumin + Midodrine (5mg thrice daily&#xD;
           and will be increased every 3 days upto 15 mg thrice daily with target MAP (&gt;75 mm and&#xD;
           &lt;90) and Group B with SMT + Albumin: 80grams/week for 2 weeks followed by 40gram/week +&#xD;
           Placebo&#xD;
&#xD;
      Stopping ruleAdverse reaction to Albumin&#xD;
&#xD;
        -  Cardiopulmonary compromise&#xD;
&#xD;
        -  Allergic reaction&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2021</start_date>
  <completion_date type="Anticipated">March 19, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival free of transplant and TIPS</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of liver-related complications</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of liver-related complications</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of liver-related complications</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of liver transplant in both groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of TIPS in both groups</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HRS-AKD, in both groups at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HRS-CKD in both groups at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of HRS AKI in both groups at 1 year</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of large volume paracentesis</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of large volume paracentesis</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative frequency of large volume paracentesis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in fraility</measure>
    <time_frame>3 months</time_frame>
    <description>AS PER MAYO FRAITITY INDEX , FRAITILY IS CLASSIFIED AS PRE FRAIL, FRAIL AND ROBUST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in fraility</measure>
    <time_frame>6 months</time_frame>
    <description>AS PER MAYO FRAITITY INDEX , FRAITILY IS CLASSIFIED AS PRE FRAIL, FRAIL AND ROBUST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in fraility</measure>
    <time_frame>12 months</time_frame>
    <description>AS PER MAYO FRAITITY INDEX , FRAITILY IS CLASSIFIED AS PRE FRAIL, FRAIL AND ROBUST.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of TIPS</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival free of transplant at 6 months</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Liver Cirrhosis</condition>
  <arm_group>
    <arm_group_label>Midodrine + Albumin +Standard Medical Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SMT + Albumin + Midodrine (5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (&gt;75 mm and &lt;90).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin + Standard Medical Treatment+ Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>80grams/week for 2 weeks followed by 40gram/week + Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Midodrine</intervention_name>
    <description>5mg thrice daily and will be increased every 3 days upto 15 mg thrice daily with target MAP (&gt;75 mm and &lt;90)</description>
    <arm_group_label>Midodrine + Albumin +Standard Medical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Albumin</intervention_name>
    <description>80grams/week for 2 weeks followed by 40gram/week</description>
    <arm_group_label>Albumin + Standard Medical Treatment+ Placebo</arm_group_label>
    <arm_group_label>Midodrine + Albumin +Standard Medical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard Medical Treatment</intervention_name>
    <description>Standard Medical Treatment</description>
    <arm_group_label>Albumin + Standard Medical Treatment+ Placebo</arm_group_label>
    <arm_group_label>Midodrine + Albumin +Standard Medical Treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Albumin + Standard Medical Treatment+ Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - Cirrhosis with refractory ascites&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - Recent Gastrointestinal bleeding within 7 days&#xD;
&#xD;
          -  Systemic arterial hypertension (&gt;160/90mmhg)&#xD;
&#xD;
          -  Presence of hepatocellular carcinoma or portal vein thrombosis, Budd-chiari syndrome.&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  No use of drugs affecting systemic hemodynamics 7 days prior to enrolment&#xD;
&#xD;
          -  Patients with Cardiovascular disease (NYHA &gt; II) or chronic obstructive pulmonary&#xD;
             disease&#xD;
&#xD;
          -  Refusal to participate&#xD;
&#xD;
          -  Known or suspected hypersensitivity to albumin&#xD;
&#xD;
          -  Prior TIPS&#xD;
&#xD;
          -  Post liver or kidney transplantation&#xD;
&#xD;
          -  Patients enrolled in other clinical trials&#xD;
&#xD;
          -  Extrahepatic malignancy&#xD;
&#xD;
          -  Patients on cardiac glycosides like digoxin, phenylephrine, ephedrine, thyroid&#xD;
             hormones, ergot derivatives, salt retaining steroids like fludrocortisone, MAO&#xD;
             inhibitors, alpha blockers metformin and ranitidine (known to have interactions with&#xD;
             midodrine)&#xD;
&#xD;
          -  Patients with intrinsic kidney disease, organ nephropathy and CKD stage 4 and&#xD;
&#xD;
          -  MELD &gt; 30 and extremely moribend patient&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Priti Gupta, MD</last_name>
    <phone>01146300000</phone>
    <email>priti7vns@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institute of Liver &amp; Biliary Sciences</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <zip>110070</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Priti Gupta, MD</last_name>
      <phone>01146300000</phone>
      <email>priti7vns@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 15, 2021</study_first_submitted>
  <study_first_submitted_qc>March 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 25, 2021</study_first_posted>
  <last_update_submitted>June 12, 2021</last_update_submitted>
  <last_update_submitted_qc>June 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Ascites</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Midodrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

